PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Korean Post-marketing Surveillance for Xeljanz XR

Recruiting

Conditions: Active Moderate to Severe Rheumatoid Arthritis
Active Ankylosing Spondylitis
Active Psoriatic Arthritis

First Posted Date: 2021-05-06

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT04876781

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13vPnC
Biological: 20vPnC
Other: Saline
Biological: PPSV23

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 1425

Registration Number: NCT04875533

Locations: 🇯🇵
Seishinkai Inoue Hospital, Itoshima, Fukuoka, Japan
🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵
Fukuwa Clinic, Chuo-ku, Tokyo, Japan

and more 25 locations

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Oral [14C]PF-06865571
Drug: Oral PF-06865571
Drug: IV [14C]PF-06865571

First Posted Date: 2021-04-29

Last Posted Date: 2024-07-31

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04866225

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07038124 or vehicle

First Posted Date: 2021-04-28

Last Posted Date: 2024-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04863417

Locations: 🇯🇵
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Crizotinib

First Posted Date: 2021-04-23

Last Posted Date: 2022-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT04856293

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study in Healthy Adults Evaluating PF-07202954

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease
Liver Fibrosis

Interventions: Drug: PF-07202954 Single Dose
Drug: PF-07202954 Repeat Dose
Drug: Placebo

First Posted Date: 2021-04-23

Last Posted Date: 2021-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04857437

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

Phase 2

Terminated

Conditions: Microvascular Obstruction

Interventions: Drug: Temanogrel
Drug: Placebo

First Posted Date: 2021-04-19

Last Posted Date: 2023-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04848220

Locations: 🇬🇧
East and North Hertfordshire NHS Trust Lister Hospital, Stevenage, United Kingdom
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia

and more 9 locations

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

Recruiting

Conditions: COVID-19

Interventions: Biological: XBB.1.5-adapted vaccinated
Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Biological: BNT162b2 BA.4/5 bivalent

First Posted Date: 2021-04-19

Last Posted Date: 2025-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 999

Registration Number: NCT04848584

Locations: 🇺🇸
Kaiser Permanente Southern California, Pasadena, California, United States

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3

Completed

Conditions: Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Glasdegib
Drug: Azacitidine

First Posted Date: 2021-04-13

Last Posted Date: 2023-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT04842604

Locations: 🇦🇹
Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU, Salzburg, Austria
🇭🇺
Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek, Debrecen, Hungary
🇦🇹
Uniklinikum Salzburg, Landeskrankenhaus Salzburg, Salzburg, Austria

and more 15 locations

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: PF-06882961 + PF-06865571
Drug: PF-06882961 followed by PF-06882961/PF-06865571
Drug: PF-06882961/PF-06865571 followed by PF-06882961

First Posted Date: 2021-04-09

Last Posted Date: 2023-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT04839393

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy